DarioHealth (DRIO) said Thursday that a health insurer in the US extended its agreement with the company and expanded the scope by adding its AI-powered hypertension offering.
The insurer's roll out of Dario's cardiometabolic care has the potential to triple the company's revenue opportunity under the deal, according to a statement.
Revenue contribution from the expanded program is expected in 2026, with higher impact 2027 onward, according to the company.
Under the revised deal, eligible members can access Dario's offering across the full blood pressure continuum, potentially supporting earlier intervention, the company said.
Price: $7.15, Change: $+0.33, Percent Change: +4.84%